Amifampridine
- Atc Codes:N07XX05
- CAS Codes:54-96-6
- PHARMGKB ID:54-96-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Firdapse; Bulgaria: Firdapse; Czech Republic: Firdapse; Estonia: Firdapse; Germany: Firdapse; Latvia: Firdapse; Lithuania: Firdapse; Luxembourg: Firdapse; Malta: Firdapse; Netherlands: Firdapse; Poland: Zenas; Portugal: Firdapse; Slovakia: Firdapse; Slovenia: Firdapse; Sweden: Firdapse.
Drug combinations
Chemistry
Amifampridine Phosphate: C~5~H~7~N~3~ HPO~4~^2^-. 3,4-diaminopyridine phosphate (DAPP). CAS-54-96-6.
Pharmacologic Category
Central Nervous System Agents, Miscellaneous; Pyridine Derivatives. (ATC-Code: N07XX05).
Mechanism of action
Amifampridine blocks voltage-dependent potassium channels, thereby prolonging pre-synaptic cell membrane depolarization. Prolonging the action potential enhances the transport of calcium into the nerve ending. The resulting increase in intra-cellular calcium concentrations facilitates exocytosis of acetylcholine-containing vesicles, which in turn enhances neuromuscular transmission.
Therapeutic use
Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Pregnancy and lactiation implications
Should not be used during pregnancy and breast-feeding.
Unlabeled use
Contraindications
Hypersensitivity to the active substance, or to any of the excipients. Epilepsy. Uncontrolled asthma. Concomitant use with sultopride. Concomitant use with medicinal products with a narrow therapeutic window. Concomitant use with medicinal products with a known potential to cause QTc prolongation. In patients with congenital QT syndromes.
Warnings and precautions
Exposure to amifampridine is associated with an increased risk for epileptic seizures (dose-dependent adverse effect; increased in patients with risk factors which lower the epileptic threshold; treatment should be discontinued in the event of a seizure). Clinical and electrocardiogram (ECG) monitoring are indicated.